SENS vs. EYPT, TRNS, ALNT, AEHR, CTKB, LAB, FEIM, QTRX, MASS, and QSI
Should you be buying Senseonics stock or one of its competitors? The main competitors of Senseonics include Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Allient (ALNT), Aehr Test Systems (AEHR), Cytek Biosciences (CTKB), Standard BioTools (LAB), Frequency Electronics (FEIM), Quanterix (QTRX), 908 Devices (MASS), and Quantum-Si (QSI). These companies are all part of the "measuring and control equipment" industry.
Senseonics vs. Its Competitors
Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Senseonics (NYSE:SENS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.
Eyepoint Pharmaceuticals currently has a consensus target price of $26.86, indicating a potential upside of 131.53%. Senseonics has a consensus target price of $1.54, indicating a potential upside of 234.24%. Given Senseonics' stronger consensus rating and higher possible upside, analysts plainly believe Senseonics is more favorable than Eyepoint Pharmaceuticals.
Eyepoint Pharmaceuticals has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Senseonics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.
Senseonics has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Senseonics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.4% of Senseonics shares are owned by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Senseonics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Eyepoint Pharmaceuticals had 7 more articles in the media than Senseonics. MarketBeat recorded 7 mentions for Eyepoint Pharmaceuticals and 0 mentions for Senseonics. Senseonics' average media sentiment score of 1.27 beat Eyepoint Pharmaceuticals' score of 1.22 indicating that Senseonics is being referred to more favorably in the news media.
Eyepoint Pharmaceuticals has a net margin of -337.93% compared to Senseonics' net margin of -362.30%. Eyepoint Pharmaceuticals' return on equity of -63.80% beat Senseonics' return on equity.
Summary
Eyepoint Pharmaceuticals beats Senseonics on 10 of the 17 factors compared between the two stocks.
Get Senseonics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SENS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Senseonics Competitors List
Related Companies and Tools
This page (NYSE:SENS) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access